Work

First Successful Treatment Reported with Pembrolizumab in a Patient Diagnosed with Choriocarcinoma in Hungary

Year: 2026

Type: article

Abstract: Pembrolizumab is a programmed cell death protein (PD-1) inhibitor, humanized antibody widely used in cancer immunotherapy. Choriocarcinoma is an aggressive type of gestational trophoblastic neoplasia. Its treatment is based on surgical removal of the tumorous tissue and systemic chemotherapy; however, in some chemoresistant cases, immunotherapy can also be a valid option. Here, we report the first successful programmed death inhibitor-based treatment of a patient diagnosed with stage IV, ultra-high-risk choriocarcinoma in Hungary.

Source: Life

DOI: 10.3390/life16030481

Authors: Kornel Fulop Lakatos, László Kalmár, Erika Lahm, Erzsébet Gyöngyvirág Bíró, Vilmos Fülöp

Institutions: Széchenyi István University, National Institute of Oncology, University of Miskolc

Language: English

Topic: Gestational Trophoblastic Disease Studies

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,137